Your session is about to expire
← Back to Search
Capmatinib Safety for Cancer
Study Summary
This trial is to study the long-term safety of a drug called capmatinib, which is given to patients who are judged to benefit from the treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently on capmatinib treatment in a Novartis study and can move to another study.I have not received any live vaccines in the last 30 days.I am not on any study treatment now due to ongoing side effects.I am willing and able to follow the study's schedule and procedures.I am currently benefiting from the treatment in this study.I am not using effective birth control while on the study treatment.
- Group 1: Capmatinib
- Group 2: Capmatinib + Nazartinib
- Group 3: Capmatinib + Gefitinib
- Group 4: Capmatinib + Osimertinib
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people total will be taking part in this clinical trial?
"That is correct. The clinical trial, which was first posted on July 4th 2017 and last edited on October 5th 2020, appears to be actively recruiting patients. Currently, the study needs 40 individuals between its 2 planned locations."
When will capmatinib be available for public use?
"Capmatinib's safety is supported by some data, but as this is only a Phase 2 trial, there is no clinical evidence yet of the medication's efficacy. Therefore, we gave it a score of 2."
Are patients being enrolled in this clinical trial at present?
"The clinical trial is actively recruiting patients, as shown by the updated information on clinicaltrials.gov. The trial was originally posted on 7/4/2017, and the most recent update was 10/5/2022. The study requires 40 patients from 2 locations."
Are there other similar medical studies that have tested the effects of capmatinib?
"44 clinical trials are investigating the efficacy of capmatinib with 17 of them in Phase 3. Most of these medical studies are taking place in Chuo-Ku, Tokyo; however, there are 873 research sites for this drug globally."
Share this study with friends
Copy Link
Messenger